ArticleCureus2025
Outcome of Pulmonary Large Cell Neuroendocrine Carcinoma After Definitive Treatment: A Single-Center Retrospective Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive form of lung cancer. Given its poor prognosis and limited representation in clinical trials, the optimal treatment strategy remains undefined. This study aims to evaluate treatment modalities and clinical outcomes among LCNEC patients who received definitive treatment. Methods A retrospective review was conducted for patients diagnosed with LCNEC from 2000 to 2022 in a tertiary center. Clinical characteristics, staging, treatment modalities, molecular testing, and survival outcomes were collected. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier estimates. Results Twenty-seven patients were included. The median age was 69.6 years; most were male (92.6%) and smokers (92.6%). Distribution by stage was as follows: I (29.6%), II (22.2%), and III (48.1%). Surgery was performed in 77.8%, and 33.3% received chemoradiotherapy. Adjuvant platinum-etoposide chemotherapy was administered in 42.8% of surgical cases. With a median follow-up of 75.9 months, the median PFS and OS were 9.6 and 20.8 months, respectively. The median OS by stage was as follows: I (30.2 months), II (23.5 months), and III (14.9 months). The recurrence rate was high (85.2%), with distant relapse being the most common (63%). Locoregional control was achieved in 40.7% of patients. Actionable mutations were detected in one patient (3.7%), and comprehensive molecular testing was underutilized. Conclusion LCNEC remains a clinically aggressive tumor with poor outcomes despite definitive treatment. The high recurrence rate, particularly in advanced stages, highlights the need for improved systemic strategies. Broader adoption of molecular profiling may uncover therapeutic targets and support the integration of emerging treatments, including immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.